Previous 10 | Next 10 |
DURECT Corporation (DRRX) Q4 2021 Earnings Conference Call March 7, 2022, 4:30 PM ET Company Participants Mike Arenberg - Chief Financial Officer Matt Hogan - Former Chief Financial Officer Jim Brown - President and CEO Dr. WeiQi Lin - Executive Vice President, R&D and Principal Scientist...
Durect press release (NASDAQ:DRRX): Q4 GAAP EPS of -$0.03 beats by $0.02. Revenue of $7.3M (+230.3% Y/Y) beats by $5.2M. At December 31, 2021, cash and investments were $70.0 million For further details see: Durect GAAP EPS of -$0.03 beats by $0.02, revenue of $7.3M beats by $5.2M
DURECT Corporation Reports Fourth Quarter and Full Year 2021 Financial Results and Update of Programs - Webcast of Earnings Call Today, March 7th at 4:30 p.m. ET - Dosed first patient in Europe in the AHFIRM trial - Signed a licensing agreement for POSIMIR® for up t...
The clinical-stage pharma company, Durect Corporation (DRRX -3.9%) is trading lower for the fourth straight session on Monday as the investors react to the resignation of its Chief Financial Officer, Michael Arenberg, with effect from Mar. 17. In response, Durect (NASDAQ:DRRX) has appointed J...
BATL, CLAR, DRRX, EARN, IDT, IEA, IPI, LFMD, MASS, ROCC, VMD For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Monday's close
DURECT Corporation Doses First European Patient in Phase 2b AHFIRM Study of Larsucosterol(DUR-928) in Severe Alcohol-Associated Hepatitis PR Newswire CUPERTINO, Calif. , March 1, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it dosed ...
DURECT Corporation to Announce Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on March 7 PR Newswire CUPERTINO, Calif. , Feb. 28, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its f...
DURECT Corporation to Participate in H.C. Wainwright Bioconnect Conference PR Newswire CUPERTINO, Calif. , Jan. 6, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown , President and CEO, Michael H. Arenberg ...
DURECT and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR® (Bupivacaine Solution) - DURECT to receive near-term upfront cash payments totaling $6 million, potential additional milestone payments of up to $130 million and tiered low to mid double-digit...
DURECT Corporation Expands Board of Directors with Appointment of Biopharmaceutical Industry Finance Veteran Peter Garcia PR Newswire CUPERTINO, Calif. , Dec. 14, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the expansion of its boar...
News, Short Squeeze, Breakout and More Instantly...
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis PR Newswire DURECT plans to confirm the efficacy and safety of larsucosterol in a registrational Phase 3 clinical trial CUPERTINO, Calif. , May ...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 171.6% to $0.1657 on volume of 180,907,472 shares AMC Entertainment Holdings Inc. Class A (AMC) rose 84.4% to $9.57 on volume of 174,658,682 shares Plug Power Inc. (PLUG) rose 45.9%...
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update PR Newswire - FDA Feedback Supports Single Pivotal Trial for Approval of Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Ea...